Document Detail


The effect of flosequinan in patients with heart failure of acute onset complicating acute myocardial infarction.
MedLine Citation:
PMID:  2668206     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We studied the hemodynamic effect of a single dose of the new direct-acting vasodilator, flosequinan, in 18 patients with severe heart failure of acute onset complicating acute myocardial infarction, which was resistant to high doses of diuretics, nitrates and dobutamine given intravenously. Flosequinan was added to conventional therapy at 3.5 +/- 0.8 days from the infarction, in the form of a single oral dose of 100 mg. Hemodynamic measurements were performed every hour for 4 hours after the administration, without any other drug being added. The infusion rate of nitrates was kept constant. Flosequinan produced hemodynamic improvement in this group. The effect peaked at 2 hours and remained at this level at 4 hours. Pulmonary capillary wedge pressure decreased from 27.6 +/- 4.3 to 16.8 +/- 2.8 mm Hg and cardiac output increased from 3.5 +/- 0.3 to 4.1 +/- 0.4 l/min (P less than 0.001). Pulmonary arterial and right atrial pressures and systemic and pulmonary vascular resistances were also significantly reduced. Heart rate and mean systemic arterial pressure were not significantly altered. Administration of flosequinan was not associated with symptomatic hypotension, cardiac arrhythmias or other adverse events. We conclude that flosequinan is effective in producing acute hemodynamic improvement in patients with heart failure, complicating acute myocardial infarction, which is resistant to conventional therapy. Flosequinan is safe and well tolerated. Studies for longer time periods are indicated.
Authors:
A Schneeweiss; R D Wynne; A Marmor
Related Documents :
2936956 - A prospective randomized clinical trial of intracoronary streptokinase versus coronary ...
4075606 - Intravenous versus intracoronary streptokinase in acute myocardial infarction.
6358886 - Western washington randomized trial of intracoronary streptokinase in acute myocardial ...
21309746 - C-terminal provasopressin (copeptin) as a prognostic marker after acute non-st elevatio...
14760986 - Noonan syndrome associated with anomalous coronary artery and other cardiac defects.
15851616 - Late gadolinium enhancement cardiovascular magnetic resonance of the systemic right ven...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  International journal of cardiology     Volume:  24     ISSN:  0167-5273     ISO Abbreviation:  Int. J. Cardiol.     Publication Date:  1989 Jul 
Date Detail:
Created Date:  1989-09-08     Completed Date:  1989-09-08     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8200291     Medline TA:  Int J Cardiol     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  73-6     Citation Subset:  IM    
Affiliation:
Geriatric Cardiology Research Foundation, Geneva, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Adult
Aged
Clinical Trials as Topic
Female
Heart Failure / drug therapy*
Hemodynamics / drug effects
Humans
Male
Middle Aged
Myocardial Infarction / complications*
Quinolines / therapeutic use*
Vasodilator Agents / therapeutic use*
Chemical
Reg. No./Substance:
0/Quinolines; 0/Vasodilator Agents; 76568-02-0/flosequinan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Polymorphism of the c-Ha-ras-1 proto-oncogene in sporadic and familial breast cancer.
Next Document:  Epidemiology of coronary arterial disease in the Chinese.